Zacks: Brokerages Anticipate Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to Post -$0.65 Earnings Per Share

Share on StockTwits

Brokerages forecast that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will post earnings per share (EPS) of ($0.65) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.45). Enanta Pharmaceuticals posted earnings of $0.33 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 297%. The firm is expected to report its next earnings results on Tuesday, August 4th.

On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($1.40) to ($0.23). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.70) per share, with EPS estimates ranging from ($4.12) to ($1.07). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.43. The firm had revenue of $27.60 million during the quarter, compared to the consensus estimate of $29.16 million. Enanta Pharmaceuticals had a return on equity of 5.04% and a net margin of 13.46%. The firm’s revenue for the quarter was down 30.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share.

ENTA has been the subject of a number of recent research reports. Royal Bank of Canada reiterated a “hold” rating and set a $49.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, April 8th. Oppenheimer reiterated a “hold” rating and set a $62.00 price objective on shares of Enanta Pharmaceuticals in a research report on Thursday, May 7th. ValuEngine downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 7th. Robert W. Baird upgraded Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $60.00 price objective for the company in a research report on Tuesday, March 17th. Finally, BidaskClub downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Enanta Pharmaceuticals has a consensus rating of “Hold” and an average target price of $68.50.

A number of large investors have recently made changes to their positions in ENTA. PNC Financial Services Group Inc. raised its stake in Enanta Pharmaceuticals by 39.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,068 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 301 shares during the period. Bank of Montreal Can increased its stake in shares of Enanta Pharmaceuticals by 26.2% in the fourth quarter. Bank of Montreal Can now owns 2,642 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 548 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of Enanta Pharmaceuticals by 609.4% in the fourth quarter. Quantbot Technologies LP now owns 3,015 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 2,590 shares during the last quarter. IndexIQ Advisors LLC acquired a new position in shares of Enanta Pharmaceuticals in the first quarter worth $190,000. Finally, Amalgamated Bank acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth $207,000. 89.01% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ENTA opened at $49.04 on Friday. Enanta Pharmaceuticals has a one year low of $38.40 and a one year high of $89.25. The stock has a fifty day moving average of $51.63 and a 200-day moving average of $53.90. The company has a market capitalization of $981.01 million, a PE ratio of 43.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.63 and a current ratio of 20.64.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

InnerWorkings  & CardioGenics  Head-To-Head Contrast
InnerWorkings & CardioGenics Head-To-Head Contrast
Head to Head Analysis: Castlight Health  vs. JMU Ltd-
Head to Head Analysis: Castlight Health vs. JMU Ltd-
Financial Comparison: ChampionX  vs. Ecosphere Technologies
Financial Comparison: ChampionX vs. Ecosphere Technologies
Financial Survey: Mimecast  versus Cloudflare
Financial Survey: Mimecast versus Cloudflare
Analyzing Curaegis Technologies  & American Axle & Manufact.
Analyzing Curaegis Technologies & American Axle & Manufact.
Bloom Energy Corp  Expected to Post Quarterly Sales of $168.93 Million
Bloom Energy Corp Expected to Post Quarterly Sales of $168.93 Million


© 2006-2020 Ticker Report